EAN 2026: MS Copilot shows promise in monitoring disability progression in MS

Sanofi/Ad Scientiam presented an interim analysis from the ongoing MS-DETECT (NCT05816122) study, showing that Microsoft (MS) ...
KTLA

MSCopilot® receives CE marking under the European Union Medical Device Regulation (EU MDR) 2017/745

PARIS, FRANCE, FRANCE, June 3, 2025 /EINPresswire.com/ -- On the occasion of World Multiple Sclerosis Day, Ad Scientiam announced that MSCopilot ®, its class IIa ...
The Anderson Independent-Mail

Ad Scientiam launches U.S. subsidiary and expands deployment of MSCopilot® following FDA registration

Ad Scientiam announces the creation of its U.S. subsidiary, Ad Scientiam Inc., to support the deployment of MSCopilot® in the United States. The launch of Ad Scientiam Inc. in the U.S. marks a major ...
WGN Radio

Ad Scientiam Launches a Pilot Project in the U.S. to Assess MSCopilot®’s Integration into Routine Care for MS Patients

PARIS, FRANCE, February 26, 2025 /EINPresswire.com/ -- Ad Scientiam, a pioneering MedTech company specialized in digital biomarkers, announced today the launch of MS ...
WIVB-TV

Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot

Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination ...
Mena FN

Ad Scientiam Launches U.S. Subsidiary And Expands Deployment Of Mscopilot® Following FDA Registration

(MENAFN- EIN Presswire) EINPresswire/ -- Ad Scientiam, a global leader in digital biomarkers, today announced the creation of its U.S. subsidiary, Ad Scientiam Inc., incorporated in the state of ...